Conatus Pharmaceuticals (CNAT): Jumping On The Zika Train - FBR

August 30, 2016 8:17 AM EDT
Get Alerts CNAT Hot Sheet
Price: $1.92 --0%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 19 | New: 11
Trade CNAT Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

FBR Capital analyst, Vernon Bernadino, reiterated his Outperform rating on shares of Conatus Pharmaceuticals (NASDAQ: CNAT) after research published in the journal Nature Medicine by scientists at the National Institutes of Health (NIH) and its collaborators showed that emricasan, a small molecule, pan caspase inhibitor in Phase II development for liver cirrhosis (LC) by Conatus Pharmaceuticals, is effective in reducing the ability of Zika virus (ZIKV) to kill brain cells.

The analyst has no knowledge of any further clinical activities with emricasan in ZIKV; however, the results pose an intriguing and positive development for Conatus, as interest in emricasan by the broader medical community could accelerate its path to regulatory approval.

No change to the price target of $16.

For an analyst ratings summary and ratings history on Conatus Pharmaceuticals click here. For more ratings news on Conatus Pharmaceuticals click here.

Shares of Conatus Pharmaceuticals closed at $2.00 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Add Your Comment